Literature DB >> 19833728

Pivotal role of the C-terminal DW-motif in mediating inhibition of pyruvate dehydrogenase kinase 2 by dichloroacetate.

Jun Li1, Masato Kato, David T Chuang.   

Abstract

The mitochondrial pyruvate dehydrogenase complex (PDC) is down-regulated by phosphorylation catalyzed by pyruvate dehydrogenase kinase (PDK) isoforms 1-4. Overexpression of PDK isoforms and therefore reduced PDC activity prevails in cancer and diabetes. In the present study, we investigated the role of the invariant C-terminal DW-motif in inhibition of human PDK2 by dichloroacetate (DCA). Substitutions were made in the DW-motif (Asp-382 and Trp-383) and its interacting residues (Tyr-145 and Arg-149) in the other subunit of PDK2 homodimer. Single and double mutants show 20-60% residual activities that are not stimulated by the PDC core. The R149A and Y145F/R149A mutants show drastic increases in apparent IC(50) values for DCA, whereas binding affinities for DCA are comparable with wild-type PDK2. Both R149A and Y145F variants exhibit increased similar affinities for ADP and ATP, mimicking the effects of DCA. The R149A and the DW-motif mutations (D382A/W383A) forestall binding of the lipoyl domain of PDC to these mutants, analogous to wild-type PDK2 in the presence of DCA and ADP. In contrast, the binding of a dihydrolipoamide mimetic AZD7545 is largely unaffected in these PDK2 variants. Our results illuminate the pivotal role of the DW-motif in mediating communications between the DCA-, the nucleotide-, and the lipoyl domain-binding sites. This signaling network locks PDK2 in the inactive closed conformation, which is in equilibrium with the active open conformation without DCA and ADP. These results implicate the DW-motif anchoring site as a drug target for the inhibition of aberrant PDK activity in cancer and diabetes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19833728      PMCID: PMC2797213          DOI: 10.1074/jbc.M109.065557

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

Review 1.  Molecular biology and biochemistry of pyruvate dehydrogenase complexes.

Authors:  M S Patel; T E Roche
Journal:  FASEB J       Date:  1990-11       Impact factor: 5.191

Review 2.  Pathogenesis and treatment of lipoprotein disorders.

Authors:  P Stacpoole
Journal:  Compr Ther       Date:  1989-04

3.  Dihydrolipoamide dehydrogenase-binding protein of the human pyruvate dehydrogenase complex. DNA-derived amino acid sequence, expression, and reconstitution of the pyruvate dehydrogenase complex.

Authors:  R A Harris; M M Bowker-Kinley; P Wu; J Jeng; K M Popov
Journal:  J Biol Chem       Date:  1997-08-08       Impact factor: 5.157

4.  Regulation of mammalian pyruvate and branched-chain alpha-keto acid dehydrogenase complexes by phosphorylation-dephosphorylation.

Authors:  L J Reed; Z Damuni; M L Merryfield
Journal:  Curr Top Cell Regul       Date:  1985

5.  Function of phosphorylation sites on pyruvate dehydrogenase.

Authors:  W M Teague; F H Pettit; S J Yeaman; L J Reed
Journal:  Biochem Biophys Res Commun       Date:  1979-03-15       Impact factor: 3.575

6.  Critical role of a lipoyl cofactor of the dihydrolipoyl acetyltransferase in the binding and enhanced function of the pyruvate dehydrogenase kinase.

Authors:  G A Radke; K Ono; S Ravindran; T E Roche
Journal:  Biochem Biophys Res Commun       Date:  1993-02-15       Impact factor: 3.575

7.  Analysis of site occupancies in [32P]phosphorylated pyruvate dehydrogenase complexes by aspartyl-prolyl cleavage of tryptic phosphopeptides.

Authors:  G J Sale; P J Randle
Journal:  Eur J Biochem       Date:  1981-12

8.  Pharmacokinetics of dichloroacetate in adult patients with lactic acidosis.

Authors:  G N Henderson; S H Curry; H Derendorf; E C Wright; P W Stacpoole
Journal:  J Clin Pharmacol       Date:  1997-05       Impact factor: 3.126

9.  Binding of the pyruvate dehydrogenase kinase to recombinant constructs containing the inner lipoyl domain of the dihydrolipoyl acetyltransferase component.

Authors:  S Liu; J C Baker; T E Roche
Journal:  J Biol Chem       Date:  1995-01-13       Impact factor: 5.157

10.  Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance.

Authors:  Chun-Wun Lu; Shih-Chieh Lin; Ko-Fan Chen; Yen-Yu Lai; Shaw-Jenq Tsai
Journal:  J Biol Chem       Date:  2008-08-21       Impact factor: 5.157

View more
  12 in total

1.  Furoates and thenoates inhibit pyruvate dehydrogenase kinase 2 allosterically by binding to its pyruvate regulatory site.

Authors:  Tiziana Masini; Barbara Birkaya; Simon van Dijk; Milon Mondal; Johan Hekelaar; Manuel Jäger; Anke C Terwisscha van Scheltinga; Mulchand S Patel; Anna K H Hirsch; Edelmiro Moman
Journal:  J Enzyme Inhib Med Chem       Date:  2016-07-19       Impact factor: 5.051

Review 2.  Mammalian NADH:ubiquinone oxidoreductase (Complex I) and nicotinamide nucleotide transhydrogenase (Nnt) together regulate the mitochondrial production of H₂O₂--implications for their role in disease, especially cancer.

Authors:  Simon P J Albracht; Alfred J Meijer; Jan Rydström
Journal:  J Bioenerg Biomembr       Date:  2011-09-01       Impact factor: 2.945

3.  Structure-guided development of specific pyruvate dehydrogenase kinase inhibitors targeting the ATP-binding pocket.

Authors:  Shih-Chia Tso; Xiangbing Qi; Wen-Jun Gui; Cheng-Yang Wu; Jacinta L Chuang; Ingrid Wernstedt-Asterholm; Lorraine K Morlock; Kyle R Owens; Philipp E Scherer; Noelle S Williams; Uttam K Tambar; R Max Wynn; David T Chuang
Journal:  J Biol Chem       Date:  2013-12-19       Impact factor: 5.157

4.  Inactivation of pyruvate dehydrogenase kinase 2 by mitochondrial reactive oxygen species.

Authors:  Thomas R Hurd; Yvonne Collins; Irina Abakumova; Edward T Chouchani; Bartlomiej Baranowski; Ian M Fearnley; Tracy A Prime; Michael P Murphy; Andrew M James
Journal:  J Biol Chem       Date:  2012-08-21       Impact factor: 5.157

Review 5.  Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target?

Authors:  Wen Zhang; Shao-Lin Zhang; Xiaohui Hu; Kin Yip Tam
Journal:  Int J Biol Sci       Date:  2015-11-01       Impact factor: 6.580

Review 6.  Targeting Cancer Metabolism - Revisiting the Warburg Effects.

Authors:  Quangdon Tran; Hyunji Lee; Jisoo Park; Seon-Hwan Kim; Jongsun Park
Journal:  Toxicol Res       Date:  2016-07-30

7.  Hemistepsin A suppresses colorectal cancer growth through inhibiting pyruvate dehydrogenase kinase activity.

Authors:  Ling Jin; Eun-Yeong Kim; Tae-Wook Chung; Chang Woo Han; So Young Park; Jung Ho Han; Sung-Jin Bae; Jong Rok Lee; Young Woo Kim; Se Bok Jang; Ki-Tae Ha
Journal:  Sci Rep       Date:  2020-12-14       Impact factor: 4.379

8.  Conserved sequence motifs in human TMTC1, TMTC2, TMTC3, and TMTC4, new O-mannosyltransferases from the GT-C/PMT clan, are rationalized as ligand binding sites.

Authors:  Birgit Eisenhaber; Swati Sinha; Chaitanya K Jadalanki; Vladimir A Shitov; Qiao Wen Tan; Fernanda L Sirota; Frank Eisenhaber
Journal:  Biol Direct       Date:  2021-01-12       Impact factor: 4.540

9.  Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents.

Authors:  Joanne E Mallinson; Dumitru Constantin-Teodosiu; Philip D Glaves; Elizabeth A Martin; Wendy J Davies; F Russell Westwood; James E Sidaway; Paul L Greenhaff
Journal:  J Physiol       Date:  2012-10-08       Impact factor: 5.182

10.  Computational Study on New Natural Compound Inhibitors of Pyruvate Dehydrogenase Kinases.

Authors:  Xiaoli Zhou; Shanshan Yu; Jing Su; Liankun Sun
Journal:  Int J Mol Sci       Date:  2016-03-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.